408 Resources in

Medshorts

By month
Blood Related
2 Min Read
24 Jun

Safety and efficacy of efbemalenograstim alfa for reducing the risk of febrile neutropenia in breast cancer patients

A recent study suggests that efbemalenograstim alfa is safe and effective for significantly decreasing the duration of severe neutropenia and the incidence of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy. This study was published in the journal, Supportive Care in Cancer.

This phase III, randomized, double-blind, placebo-controlled study included 122 subjects, who received up to 4 cycles of TA chemotherapy that included 75 mg/m2 docetaxel + 60 mg/m2 doxorubicin. The participants were randomized in a 2:1 ratio to receive either subcutaneous injection of a single dose of 20 mg of efbemalenograstim alfa or placebo on day 2 of cycle 1. All subjects were administered efbemalenograstim alfa on day 2 of cycles 2, 3, and 4. Duration of severe (grade 4) neutropenia (DSN), incidence of febrile neutropenia (FN), depth of neutrophil nadir, time to neutrophil recovery, and safety information were recorded.

At the end of the study, it was found that for the primary endpoint, mean DSN in cycle 1 for efbemalenograstim alfa and placebo was 1.3 days and 3.9 days, respectively. In cycle 1, the incidence of FN was lower in efbemalenograstim alfa group than in placebo group (4.8% vs. 25.6%). Moreover, patients required less intravenous antibiotics in the efbemalenograstim alfa group compared to the patients in the placebo group (3.6% vs. 17.9%).

Based on the above results, it can be concluded that efbemalenograstim alfa is safe and effective for reducing the risk of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy.

Safety and efficacy of efbemalenograstim alfa for reducing the risk of febrile neutropenia in breast cancer patients

A recent study suggests that efbemalenograstim alfa is safe and effective for significantly decreasing the duration of severe neutropenia and the incidence of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy. This study was published in the journal, Supportive Care in Cancer.

This phase III, randomized, double-blind, placebo-controlled study included 122 subjects, who received up to 4 cycles of TA chemotherapy that included 75 mg/m2 docetaxel + 60 mg/m2 doxorubicin. The participants were randomized in a 2:1 ratio to receive either subcutaneous injection of a single dose of 20 mg of efbemalenograstim alfa or placebo on day 2 of cycle 1. All subjects were administered efbemalenograstim alfa on day 2 of cycles 2, 3, and 4. Duration of severe (grade 4) neutropenia (DSN), incidence of febrile neutropenia (FN), depth of neutrophil nadir, time to neutrophil recovery, and safety information were recorded.

At the end of the study, it was found that for the primary endpoint, mean DSN in cycle 1 for efbemalenograstim alfa and placebo was 1.3 days and 3.9 days, respectively. In cycle 1, the incidence of FN was lower in efbemalenograstim alfa group than in placebo group (4.8% vs. 25.6%). Moreover, patients required less intravenous antibiotics in the efbemalenograstim alfa group compared to the patients in the placebo group (3.6% vs. 17.9%).

Based on the above results, it can be concluded that efbemalenograstim alfa is safe and effective for reducing the risk of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy.

Blood Related
2 Min Read
24 Jun

Safety and efficacy of efbemalenograstim alfa for reducing the risk of febrile neutropenia in breast cancer patients

A recent study suggests that efbemalenograstim alfa is safe and effective for significantly decreasing the duration of severe neutropenia and the incidence of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy. This study was published in the journal, Supportive Care in Cancer.

This phase III, randomized, double-blind, placebo-controlled study included 122 subjects, who received up to 4 cycles of TA chemotherapy that included 75 mg/m2 docetaxel + 60 mg/m2 doxorubicin. The participants were randomized in a 2:1 ratio to receive either subcutaneous injection of a single dose of 20 mg of efbemalenograstim alfa or placebo on day 2 of cycle 1. All subjects were administered efbemalenograstim alfa on day 2 of cycles 2, 3, and 4. Duration of severe (grade 4) neutropenia (DSN), incidence of febrile neutropenia (FN), depth of neutrophil nadir, time to neutrophil recovery, and safety information were recorded.

At the end of the study, it was found that for the primary endpoint, mean DSN in cycle 1 for efbemalenograstim alfa and placebo was 1.3 days and 3.9 days, respectively. In cycle 1, the incidence of FN was lower in efbemalenograstim alfa group than in placebo group (4.8% vs. 25.6%). Moreover, patients required less intravenous antibiotics in the efbemalenograstim alfa group compared to the patients in the placebo group (3.6% vs. 17.9%).

Based on the above results, it can be concluded that efbemalenograstim alfa is safe and effective for reducing the risk of febrile neutropenia in breast cancer patients undergoing myelosuppressive chemotherapy.

button
Derma
2 Min Read
21 Jun

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

Derma
2 Min Read
21 Jun

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

button
Respiratory
2 Min Read
20 Jun

iOLA associated with a reduced risk of severe postoperative pulmonary complications compared to standard lung-protective ventilation

 A study has shown that in  individuals undergoing lung resection with one-lung ventilation, individualised open-lung approach (iOLA) had a lower risk of severe postoperative pulmonary complications compared to conventional lung-protective ventilation. This study’s findings were published in the journal, Lancet Respiratory Medicine.

In this randomised controlled trial, patients aged 18 years and above were randomised into two groups: one receiving iOLA (n=670) and the other receiving standard lung-protective ventilation (n=638). The iOLA treatment involved an alveolar recruitment manoeuvre with an end-inspiratory pressure of 40 cm H2O, followed by individualised positive end-expiratory pressure (PEEP) adjusted to achieve optimal respiratory system compliance. Additionally, participants in the iOLA group received personalised postoperative respiratory support through high-flow oxygen therapy. On the other hand, participants in the standard lung-protective ventilation group received 4 cm H2O of PEEP during surgery and conventional oxygen therapy after surgery. The primary outcome measured was the occurrence of severe postoperative pulmonary complications within the first 7 days after surgery.

At the end of the study, patients in the iOLA group had a lower incidence of severe postoperative pulmonary complications within the first 7 days post-surgery compared to those in the standard lung-protective ventilation group [40 patients (6%) vs 97 patients (15%)].

According to the above study, in patients undergoing lung resection with one-lung ventilation, the utilization of iOLA was found to be linked to a decreased likelihood of experiencing severe postoperative pulmonary complications in comparison to the use of conventional lung-protective ventilation.

iOLA associated with a reduced risk of severe postoperative pulmonary complications compared to standard lung-protective ventilation

 A study has shown that in  individuals undergoing lung resection with one-lung ventilation, individualised open-lung approach (iOLA) had a lower risk of severe postoperative pulmonary complications compared to conventional lung-protective ventilation. This study’s findings were published in the journal, Lancet Respiratory Medicine.

In this randomised controlled trial, patients aged 18 years and above were randomised into two groups: one receiving iOLA (n=670) and the other receiving standard lung-protective ventilation (n=638). The iOLA treatment involved an alveolar recruitment manoeuvre with an end-inspiratory pressure of 40 cm H2O, followed by individualised positive end-expiratory pressure (PEEP) adjusted to achieve optimal respiratory system compliance. Additionally, participants in the iOLA group received personalised postoperative respiratory support through high-flow oxygen therapy. On the other hand, participants in the standard lung-protective ventilation group received 4 cm H2O of PEEP during surgery and conventional oxygen therapy after surgery. The primary outcome measured was the occurrence of severe postoperative pulmonary complications within the first 7 days after surgery.

At the end of the study, patients in the iOLA group had a lower incidence of severe postoperative pulmonary complications within the first 7 days post-surgery compared to those in the standard lung-protective ventilation group [40 patients (6%) vs 97 patients (15%)].

According to the above study, in patients undergoing lung resection with one-lung ventilation, the utilization of iOLA was found to be linked to a decreased likelihood of experiencing severe postoperative pulmonary complications in comparison to the use of conventional lung-protective ventilation.

Respiratory
2 Min Read
20 Jun

iOLA associated with a reduced risk of severe postoperative pulmonary complications compared to standard lung-protective ventilation

 A study has shown that in  individuals undergoing lung resection with one-lung ventilation, individualised open-lung approach (iOLA) had a lower risk of severe postoperative pulmonary complications compared to conventional lung-protective ventilation. This study’s findings were published in the journal, Lancet Respiratory Medicine.

In this randomised controlled trial, patients aged 18 years and above were randomised into two groups: one receiving iOLA (n=670) and the other receiving standard lung-protective ventilation (n=638). The iOLA treatment involved an alveolar recruitment manoeuvre with an end-inspiratory pressure of 40 cm H2O, followed by individualised positive end-expiratory pressure (PEEP) adjusted to achieve optimal respiratory system compliance. Additionally, participants in the iOLA group received personalised postoperative respiratory support through high-flow oxygen therapy. On the other hand, participants in the standard lung-protective ventilation group received 4 cm H2O of PEEP during surgery and conventional oxygen therapy after surgery. The primary outcome measured was the occurrence of severe postoperative pulmonary complications within the first 7 days after surgery.

At the end of the study, patients in the iOLA group had a lower incidence of severe postoperative pulmonary complications within the first 7 days post-surgery compared to those in the standard lung-protective ventilation group [40 patients (6%) vs 97 patients (15%)].

According to the above study, in patients undergoing lung resection with one-lung ventilation, the utilization of iOLA was found to be linked to a decreased likelihood of experiencing severe postoperative pulmonary complications in comparison to the use of conventional lung-protective ventilation.

button
Cardiac
2 Min Read
19 Jun

Efficacy and safety of TRE therapy in patients with dyslipidemia and hypertension

According to a recent study, telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE) therapy led to a notable reduction in mean sitting systolic blood pressure (msSBP) and low-density lipoprotein-C (LDL-C) in comparison to rosuvastatin 20 mg/ezetimibe 10 mg (RE) double therapy, or telmisartan 80 mg (T) single therapy, while maintaining similar levels of safety and tolerability. This study’s findings were published in the Journal of clinical hypertension.

In this phase III clinical trial, following a wash-out/therapeutic lifestyle change period lasting ≥4 weeks, a group of 100 eligible patients were randomly assigned to one of three treatment options (TRE, RE, or T) for a duration of 8 weeks. The primary end point of this study was to assess the effectiveness of TRE by comparing the alterations in msSBP and the mean percentage change in LDL-C levels from the initial baseline after the 8-week treatment period.

In the TRE and RE groups, the least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were -23.02 (3.04) and -7.18 (3.09) mmHg, respectively, and -14.92 (2.65) and-25.80 (2.74) mmHg in the T and TRE groups, respectively. The percentage changes in the mean (SD) LDL-C at 8 weeks compared with baseline were -0.17% (3.23%) and -54.97% (3.49%) in the T and TRE groups, respectively.

The above study demonstrated that the TRE therapy led to a significant reduction in msSBP and LDL-C when compared to RE or T therapy.

Efficacy and safety of TRE therapy in patients with dyslipidemia and hypertension

According to a recent study, telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE) therapy led to a notable reduction in mean sitting systolic blood pressure (msSBP) and low-density lipoprotein-C (LDL-C) in comparison to rosuvastatin 20 mg/ezetimibe 10 mg (RE) double therapy, or telmisartan 80 mg (T) single therapy, while maintaining similar levels of safety and tolerability. This study’s findings were published in the Journal of clinical hypertension.

In this phase III clinical trial, following a wash-out/therapeutic lifestyle change period lasting ≥4 weeks, a group of 100 eligible patients were randomly assigned to one of three treatment options (TRE, RE, or T) for a duration of 8 weeks. The primary end point of this study was to assess the effectiveness of TRE by comparing the alterations in msSBP and the mean percentage change in LDL-C levels from the initial baseline after the 8-week treatment period.

In the TRE and RE groups, the least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were -23.02 (3.04) and -7.18 (3.09) mmHg, respectively, and -14.92 (2.65) and-25.80 (2.74) mmHg in the T and TRE groups, respectively. The percentage changes in the mean (SD) LDL-C at 8 weeks compared with baseline were -0.17% (3.23%) and -54.97% (3.49%) in the T and TRE groups, respectively.

The above study demonstrated that the TRE therapy led to a significant reduction in msSBP and LDL-C when compared to RE or T therapy.

Cardiac
2 Min Read
19 Jun

Efficacy and safety of TRE therapy in patients with dyslipidemia and hypertension

According to a recent study, telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE) therapy led to a notable reduction in mean sitting systolic blood pressure (msSBP) and low-density lipoprotein-C (LDL-C) in comparison to rosuvastatin 20 mg/ezetimibe 10 mg (RE) double therapy, or telmisartan 80 mg (T) single therapy, while maintaining similar levels of safety and tolerability. This study’s findings were published in the Journal of clinical hypertension.

In this phase III clinical trial, following a wash-out/therapeutic lifestyle change period lasting ≥4 weeks, a group of 100 eligible patients were randomly assigned to one of three treatment options (TRE, RE, or T) for a duration of 8 weeks. The primary end point of this study was to assess the effectiveness of TRE by comparing the alterations in msSBP and the mean percentage change in LDL-C levels from the initial baseline after the 8-week treatment period.

In the TRE and RE groups, the least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were -23.02 (3.04) and -7.18 (3.09) mmHg, respectively, and -14.92 (2.65) and-25.80 (2.74) mmHg in the T and TRE groups, respectively. The percentage changes in the mean (SD) LDL-C at 8 weeks compared with baseline were -0.17% (3.23%) and -54.97% (3.49%) in the T and TRE groups, respectively.

The above study demonstrated that the TRE therapy led to a significant reduction in msSBP and LDL-C when compared to RE or T therapy.

button
AllergyDerma
1 Min Read
18 Jun

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

AllergyDerma
1 Min Read
18 Jun

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

button
HaematologyBlood Related
1 Min Read
17 Jun

Ibrutinib-venetoclax effective in previously untreated chronic lymphocytic leukaemia

A recent study found that ibrutinib-venetoclax continues to demonstrate its effectiveness in prolonging progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukaemia patients. This study’s findings were published in the journal, The Lancet. Oncology.

In the GLOW study, a phase 3 randomised, multicentre clinical trial, 211 patients with previously untreated chronic lymphocytic leukaemia were enrolled. These patients were randomly divided into two groups: the ibrutinib-venetoclax group (n=106) and the chlorambucil-obinutuzumab group (n=105). The primary endpoint of the study was to assess the progression-free survival of the patients, which was evaluated by an independent review committee.

The ibrutinib-venetoclax group showed better progression-free survival at a median of 46 months of follow-up (hazard ratio of 0.214). The 42-month progression-free survival rates were 74.6% for ibrutinib-venetoclax and 24.8% for chlorambucil-obinutuzumab.

To summarize, after a 4-year period of follow-up, ibrutinib-venetoclax continues to demonstrate a significant increase in progression-free survival compared to chemoimmunotherapy for patients with previously untreated chronic lymphocytic leukemia, supporting its use as a suitable first-line treatment option.

Ibrutinib-venetoclax effective in previously untreated chronic lymphocytic leukaemia

A recent study found that ibrutinib-venetoclax continues to demonstrate its effectiveness in prolonging progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukaemia patients. This study’s findings were published in the journal, The Lancet. Oncology.

In the GLOW study, a phase 3 randomised, multicentre clinical trial, 211 patients with previously untreated chronic lymphocytic leukaemia were enrolled. These patients were randomly divided into two groups: the ibrutinib-venetoclax group (n=106) and the chlorambucil-obinutuzumab group (n=105). The primary endpoint of the study was to assess the progression-free survival of the patients, which was evaluated by an independent review committee.

The ibrutinib-venetoclax group showed better progression-free survival at a median of 46 months of follow-up (hazard ratio of 0.214). The 42-month progression-free survival rates were 74.6% for ibrutinib-venetoclax and 24.8% for chlorambucil-obinutuzumab.

To summarize, after a 4-year period of follow-up, ibrutinib-venetoclax continues to demonstrate a significant increase in progression-free survival compared to chemoimmunotherapy for patients with previously untreated chronic lymphocytic leukemia, supporting its use as a suitable first-line treatment option.

HaematologyBlood Related
1 Min Read
17 Jun

Ibrutinib-venetoclax effective in previously untreated chronic lymphocytic leukaemia

A recent study found that ibrutinib-venetoclax continues to demonstrate its effectiveness in prolonging progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukaemia patients. This study’s findings were published in the journal, The Lancet. Oncology.

In the GLOW study, a phase 3 randomised, multicentre clinical trial, 211 patients with previously untreated chronic lymphocytic leukaemia were enrolled. These patients were randomly divided into two groups: the ibrutinib-venetoclax group (n=106) and the chlorambucil-obinutuzumab group (n=105). The primary endpoint of the study was to assess the progression-free survival of the patients, which was evaluated by an independent review committee.

The ibrutinib-venetoclax group showed better progression-free survival at a median of 46 months of follow-up (hazard ratio of 0.214). The 42-month progression-free survival rates were 74.6% for ibrutinib-venetoclax and 24.8% for chlorambucil-obinutuzumab.

To summarize, after a 4-year period of follow-up, ibrutinib-venetoclax continues to demonstrate a significant increase in progression-free survival compared to chemoimmunotherapy for patients with previously untreated chronic lymphocytic leukemia, supporting its use as a suitable first-line treatment option.

button
Cardiac
2 Min Read
14 Jun

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

Cardiac
2 Min Read
14 Jun

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

button
Allergy
1 Min Read
13 Jun

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

Allergy
1 Min Read
13 Jun

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

button
1538 Resources in

Videos

View all
423 Resources in

Webinars

View all
1 Resources in

Courses

View all